IBRN vs. IDNA

Last updated Jun 24, 2026

IBRN (iShares Neuroscience and Healthcare ETF) and IDNA (iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund) are both Health & Biotech Equities funds from iShares - IBRN tracks the NYSE FactSet Global Neuro Biopharma and MedTech Index while IDNA tracks the NYSE FactSet Global Genomics and Immuno Biopharma Index. Both are passively managed. Over the past 3 years, IBRN returned 14.72%/yr vs 11.16%/yr for IDNA. A 0.79 correlation means they provide meaningful diversification when combined. Both charge a 0.47% expense ratio.

Performance

IBRN vs. IDNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in iShares Neuroscience and Healthcare ETF (IBRN) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, IBRN achieves a 14.14% return, which is significantly lower than IDNA's 19.52% return.

IBRN

• 1D: 0.60%
• 1M: 6.49%
• YTD: 14.14%
• 6M: 14.25%
• 1Y: 71.08%
• 3Y*: 14.72%
• 5Y*: —
• 10Y*: —

IDNA

• 1D: 1.53%
• 1M: 6.29%
• YTD: 19.52%
• 6M: 16.84%
• 1Y: 54.42%
• 3Y*: 11.16%
• 5Y*: -8.18%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

IBRN vs. IDNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022
IBRN iShares Neuroscience and Healthcare ETF	14.14%	28.49%	-2.78%	0.92%	2.87%
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund	19.52%	17.26%	-0.72%	-7.63%	-20.65%

Correlation

The correlation between IBRN and IDNA is 0.80, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.80
Correlation (3Y) Calculated over the trailing 3-year period	0.78
Correlation (All Time) Calculated using the full available price history since Aug 26, 2022	0.79

The correlation between IBRN and IDNA has been stable across timeframes, ranging from 0.78 to 0.80 - a consistent structural relationship.

IBRN vs. IDNA - Sectors Allocation Comparison

Sectors	IBRN	IDNA
Healthcare	100.0%	99.3%
Basic Materials	-	-
Communication Services	-	-
Consumer Cyclical	-	-
Consumer Defensive	-	-
Energy	-	-
Financial Services	-	-
Industrials	-	0.3%
Real Estate	-	-
Technology	-	-
Utilities	-	-

Return for Risk

IBRN vs. IDNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IBRN

IBRN Risk / Return Rank: 89
IBRN Sharpe Ratio Rank: 90
IBRN Sortino Ratio Rank: 88
IBRN Omega Ratio Rank: 80
IBRN Calmar Ratio Rank: 96
IBRN Martin Ratio Rank: 93

IDNA

IDNA Risk / Return Rank: 74
IDNA Sharpe Ratio Rank: 72
IDNA Sortino Ratio Rank: 71
IDNA Omega Ratio Rank: 60
IDNA Calmar Ratio Rank: 89
IDNA Martin Ratio Rank: 78

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IBRN vs. IDNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for iShares Neuroscience and Healthcare ETF (IBRN) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	IBRN	IDNA	Difference
Sharpe ratio: Return per unit of total volatility	2.80	2.19	+0.61
Sortino ratio: Return per unit of downside risk	3.71	3.03	+0.68
Omega ratio: Gain probability vs. loss probability	1.43	1.34	+0.09
Calmar ratio: Return relative to maximum drawdown	8.12	5.13	+2.99
Martin ratio: Return relative to average drawdown	22.92	14.30	+8.62

IBRN vs. IDNA - Sharpe Ratio Comparison

The current IBRN Sharpe Ratio is 2.80, which is comparable to the IDNA Sharpe Ratio of 2.19. The chart below compares the historical Sharpe Ratios of IBRN and IDNA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

IBRN vs. IDNA - Drawdown Comparison

The maximum IBRN drawdown since its inception was -35.38%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for IBRN and IDNA.

Drawdown Indicators

	IBRN	IDNA	Difference
Max Drawdown Largest peak-to-trough decline	-35.38%	-68.26%	+32.88%
Max Drawdown (1Y) Largest decline over 1 year	-8.80%	-10.66%	+1.86%
Max Drawdown (3Y) Largest decline over 3 years	-35.38%	-29.46%	-5.92%
Max Drawdown (5Y) Largest decline over 5 years	—	-68.26%	—
Current Drawdown Current decline from peak	0.00%	-41.07%	+41.07%
Average Drawdown Average peak-to-trough decline	-9.75%	-36.28%	+26.53%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.11%	3.82%	-0.71%

Volatility

IBRN vs. IDNA - Volatility Comparison

iShares Neuroscience and Healthcare ETF (IBRN) has a higher volatility of 8.17% compared to iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) at 7.33%. This indicates that IBRN's price experiences larger fluctuations and is considered to be riskier than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	IBRN	IDNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	8.17%	7.33%	+0.84%
Volatility (6M) Calculated over the trailing 6-month period	19.20%	18.45%	+0.75%
Volatility (1Y) Calculated over the trailing 1-year period	25.50%	24.96%	+0.54%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	25.36%	28.47%	-3.11%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	25.36%	29.51%	-4.15%

IBRN vs. IDNA - Expense Ratio Comparison

Both IBRN and IDNA have an expense ratio of 0.47%.

Dividends

IBRN vs. IDNA - Dividend Comparison

IBRN's dividend yield for the trailing twelve months is around 0.87%, less than IDNA's 0.90% yield.

Position	TTM	2025	2024	2023	2022	2021	2020	2019
IBRN iShares Neuroscience and Healthcare ETF	0.87%	0.99%	0.40%	0.06%	0.00%	0.00%	0.00%	0.00%
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund	0.90%	1.18%	0.98%	1.04%	0.54%	0.70%	0.26%	0.80%

Frequently Asked Questions

Can I hold both IBRN and IDNA in my portfolio?

IBRN and IDNA have a correlation of 0.80, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, IBRN or IDNA?

IBRN has higher volatility (8.17%) compared to IDNA (7.33%). In terms of maximum drawdown, IBRN dropped -35.38% vs IDNA's -68.26%.

Which ETF is better, IBRN or IDNA?

On 3-year performance, IBRN leads with 14.72% vs 11.16% for IDNA. Both ETFs have the same 0.47% expense ratio. On volatility, IDNA has been the lower-risk option at 7.33%. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF has performed better, IBRN or IDNA?

Over the 3-year period, IBRN has performed better with a 14.72% return vs 11.16%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.

Which ETF is cheaper, IBRN or IDNA?

IBRN and IDNA have the same expense ratio: 0.47% per year.

Which ETF pays a higher dividend yield, IBRN or IDNA?

IDNA has the higher dividend yield at 0.90%, compared with 0.87% for IBRN.

What is the main difference between IBRN and IDNA?

IBRN tracks NYSE FactSet Global Neuro Biopharma and MedTech Index, while IDNA tracks NYSE FactSet Global Genomics and Immuno Biopharma Index.

Which has better risk-adjusted returns?

IBRN currently has the higher Sharpe Ratio (2.80 vs 2.19), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.